A phase 1, first-time-in-human study of MEDI9197, a TLR7/8 agonist, administered intratumorally in subjects with a solid tumor cancer.

Shilpa Gupta,Fatemeh Tavakkoli,Serguei Soukharev,Guozhi Gao,Shannon R. Morris,Jeffrey S. Miller

A phase 1, first-time-in-human study of MEDI9197, a TLR7/8 agonist, administered intratumorally in subjects with a solid tumor cancer.

2016

Shilpa Gupta
Fatemeh Tavakkoli
Serguei Soukharev
Guozhi Gao
Shannon R. Morris
Jeffrey S. Miller

TPS3095Background: Toll-like receptors (TLRs) are proteins in the innate immune system that, once bound to their ligands, directly activate innate immune cells, including myeloid dendritic cells, p...

Keywords:

TLR7
Cancer
Agonist
Pathology
Oncology
Human study
Medicine
Internal medicine
Innate immune system
Receptor
solid tumor
Cancer research
Myeloid

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations